Leonabio, Inc. (Athira Pharma, Inc.) 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 29, 2025, reports on the 2025 Annual Meeting of Stockholders held by Athira Pharma, Inc. (trading symbol: ATHA). The filing details the voting results for three key proposals. As of the record date (April 4, 2025), the company had 39,042,445 shares of common stock outstanding. Approximately 71.58% of entitled shares were present or represented by proxy at the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The following material actions were approved by stockholders:
- Election of Directors: Three Class II directors were elected to serve until 2028. Joseph Edelman, John M. Fluke, Jr., and Grant Pickering received majority support, though significant "Withhold" votes were recorded for each candidate.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Reverse Stock Split Authorization: Stockholders approved amendments to the Certificate of Incorporation to effect a reverse stock split. The Board is authorized to set the final ratio at its sole discretion among options of 5-for-1, 10-for-1, 15-for-1, or 20-for-1. This action will also reduce the total number of authorized shares.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The primary contingency noted is the Board's discretion to determine the final reverse stock split ratio within the approved range.
Key Facts for Investor Verification
- Verify the final reverse stock split ratio once determined by the Board, as this will impact share price and liquidity.
- Review the definitive proxy statement filed on April 14, 2025, for detailed rationale behind the reverse split and director nominations.
- Monitor the "Withhold" vote percentages for directors, which exceeded 30% for all three nominees, indicating potential shareholder dissent.
- Confirm the effective date of the reverse stock split and the reduction in authorized shares.